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Loss of miR-378 in prostate cancer, a common 
regulator of KLK2 and KLK4, correlates with 
aggressive disease phenotype and predicts 
the short-term relapse of the patients
Abstract: A large number of prostate cancer (PCa) 
patients receive treatment without significant benefits, 
strengthening the need for accurate prognosis, which can 
be supported by the study of miRNAs. In silico specific­
ity analysis was performed for the identification of miR­
NAs able to regulate KLK2 and KLK4 expression. Total 
RNA was extracted from prostate tissues obtained from 
PCa and benign prostate hyperplasia patients. There­
after, RNA was polyadenylated and reverse transcribed 
to cDNA, which was used for qPCR analysis. miR­378 
was predicted to target both KLK2 and KLK4 and down­
regulated levels detected in PCa patients (p = 0.050). The 
reduction of miR­378 was correlated with higher Gleason 
score (p = 0.018), larger diameter tumors (p = 0.034), and 
elevated serum PSA (p = 0.006). Regarding prognosis, 
miR­378 was able to improve risk stratification accord­
ing to Gleason score or tumor stage, while higher risk 
to recur highlighted for the patients expressing lower 
miR­378 levels. Finally, the loss of miR­378 was able to 
predict the short­term relapse of ‘high’­ and ‘very high’­
recurrence­risk patients, independent of Gleason score, 
tumor stage, PSA, and age as indicated by Kaplan­Meier 
survival curves (p = 0.030) and multivariate Cox regres­
sion analysis (p = 0.018). In conclusion, loss of miR­378 
expression increases the risk for PCa progression and 
relapse, despite active treatment.
Keywords: kallikrein­related peptidase; KLK; miR­378a; 
miR­422a; molecular tumor markers; prostate tumors.
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Introduction
Despite the ongoing debate about the reduction of pros­
tate cancer (PCa) mortality, the introduction of prostate­
specific antigen (PSA) screening of the male population is 
primarily responsible for the high rate of PCa diagnosis in 
Western populations. However, this beneficial use of PSA, 
as kallikrein­related peptidase 3 (KLK3) is largely known, 
suffers from a high rate of overdiagnosis and overtreat­
ment (Andriole et al., 2009; Schroder et al., 2009).
PCa is characterized by great heterogeneity in terms 
of disease progression rate and life­threatening potential. 
Prostate tumors range from clinically insignificant and 
not life threatening to rapidly progressive and lethal ones, 
despite active treatment. Consequently, a large number of 
patients receive radical therapy without important clinical 
benefits, which further worsens health­related quality of 
life. Risk stratification and treatment decisions are mainly 
determined by Gleason score, pathological stage, serum 
PSA levels, and patient’s life expectancy (Freedland, 2011). 
However, the diverse outcomes of the same risk group of 
patients clearly highlight the need for a more accurate risk 
stratification and prognosis of the diagnosed patients, as 
well as more personalized patient’s management.
KLK2 and KLK4 are two highly expressed members 
of the kallikrein­related peptidases (KLK) gene family in 
the prostate gland, encoding for KLK2­ and KLK4­secreted 
serine proteases, both responsible for semen liquefaction 
(Borgono et  al., 2004). KLK2 and KLK4 are significantly 
overexpressed in PCa compared to benign or normal epi­
thelium (Darson et  al., 1997; Herrala et  al., 2001; Klokk 
et al., 2007; Avgeris et al., 2011), facilitating prostate tum­
origenesis and cancer cells spread. KLK2 and KLK4 were 
able to deliver tumorigenic stimuli in prostate cells by the 
overactivation of the insulin­like growth factor (IGF) axis, 
*Corresponding author: Andreas Scorilas, Department of 
Biochemistry and Molecular Biology, University of Athens, 
Panepistimiopolis, 15701 Athens, Greece,  
e-mail: ascorilas@biol.uoa.gr
Margaritis Avgeris: Department of Biochemistry and Molecular 
Biology, University of Athens, Panepistimiopolis, 15701 Athens, 
Greece
Konstantinos Stravodimos: First Department of Urology, “Laiko” 
General Hospital, Medical School, University of Athens, Agiou 
Thoma 17, 115 27 Athens, Greece
1096   M. Avgeris et al.: miR-378 loss predicts PCa short-term relapse
through IGF­binding protein (IGFBP) degradation, the 
proteolytic cleavage of cell surface proteinase­activated 
receptors 1 and 2 (PAR1 and 2) and the stimulation of AR 
and mTOR signaling in PCa cells. Moreover, the KLK2­ 
and KLK4­mediated cleavage of extracellular matrix 
(ECM) components facilitates cancer cell invasiveness 
and bone metastasis (Avgeris et al., 2010, 2012; Mavridis 
and  Scorilas, 2010). Therefore, the regulation of KLK2 and 
KLK4 expression is critical for prostate homeostasis and 
the progression of prostate malignancy.
Although the direct AR­mediated regulation of KLK 
transcription in prostate gland is well documented, and 
several androgen response elements (AREs) have been 
identified in the promoter regions of KLK2 and KLK4 
(Lawrence et al., 2010), recent findings have drawn atten­
tion to miRNAs as a novel posttranscriptional regulators 
of KLK expression (Chow et al., 2008; Pasic et al., 2012). 
Taking into account the deregulated levels of several 
miRNAs in PCa (Porkka et al., 2007; Schaefer et al., 2010a; 
Wach et al., 2012), the identification of miRNAs targeting 
KLK2 and KLK4 and the evaluation of their clinical signifi­
cance for the patients would further support the need for 
improvement of disease prognosis.
In the present study, in an effort to improve the risk 
stratification of the PCa patients and the prediction accu­
racy of their survival outcome following treatment, we 
have identified, in silico, hsa­miRNA­378­3p (miR­378) as 
a common regulator of KLK2 and KLK4 expression, and 
thereafter, we analyzed its expression levels in PCa.
Results
miR-378-3p predicted to target KLK2 and 
KLK4 expression
Several miRNAs were predicted to bind on the 3′­UTR 
of KLK2 and KLK4 mRNAs and, thus, to regulate their 
levels. In order to achieve a good balance between sen­
sitivity and specificity, we focused on those miRNAs pre­
dicted to target KLK2 and KLK4 by multiple programs. 
The miRNAs predicted to regulate both KLK2 and KLK4 
by three or more programs are presented in Table 1. As 
shown in Table 1, hsa­miR­378­3p and hsa­miR­422a, a 
paralog of hsa­miR­378­3p, are the most probable candi­
dates to target both KLK2 and KLK4. The several variants 
of hsa­miR­378­3p (miR­378a­j and miR­422a), although 
they are encoded by different stem­loop precursors, share 
the same seed sequence and, therefore, mRNA targets. 
Among them, hsa­miR­378a­3p, previously annotated as 
hsa­miR­422b, is the predominantly expressed variant of 
the miR­378/422a family. Taking into consideration the 
increased transcriptional levels of KLK2 and KLK4 and the 
reduced miR­378 levels in prostate malignancy (Martens­
Uzunova et  al., 2012), we decided to investigate miR­378 
clinical significance for PCa patients.
Expression analysis of miR-378 in prostate 
tumors
Decreased miR­378 levels (p = 0.050; Supplemental 
Figure 1) were detected in PCa (range: 0.10–62.63 RQ units; 
median: 2.80 RQ units) compared to BPH patients (range: 
0.32–113.97 RQ units; median: 3.87 RQ units). ROC analysis 
highlighted the clinical value of miR­378 in prostate malig­
nancy to discriminate the PCa patients from the BPH ones 
(AUC: 0.597; 95% CI: 0.503–0.692; p = 0.050; Supplemental 
Figure 1), which was further confirmed by univariate logis­
tic regression analysis (OR: 0.487; 95% CI: 0.243–0.977; 
p = 0.043).
Downregulation of miR-378 correlates with 
tumors of higher Gleason score and larger 
diameter as well as elevated serum PSA levels
In order to evaluate the prognostic significance of miR­378 
for PCa, the miR­378 expression levels were analyzed 
relatively to the classical and clinically used prognostic 
markers. A statistically significant (p = 0.018) downregu­
lation of miR­378 was observed as the disease progressed 
to poorly differentiated tumors (Figure 1A). More pre­
cisely, significantly lower miR­378 levels were found in 
Gleason score  ≥  8 (median: 1.20 RQ units) and Gleason 
score 7 (median: 2.11 RQ units) tumors compared to those 
of Gleason score  ≤  6 (median: 4.37 RQ units). Addition­
ally, the reduction of miR­378 in PCa was found to cor­
relate with higher PSA serum levels as significantly 
lower (p = 0.006) miR­378 expression was detected in 
PSA ≥  10 μg/l cohort (median: 1.34 RQ units) compared to 
4–10 μg/l (median: 4.08 RQ units) and  < 4 μg/l (median: 
11.06 RQ units) cohorts (Figure 1B). This negative correla­
tion between miR­378 and PSA levels was also supported 
by Spearman’s correlation coefficient (rs: ­0.273; p = 0.021; 
Figure 1C). Finally, miR­378 expression was also found to 
correlate with larger tumor diameter in PCa patients, as 
illustrated by Spearman’s correlation (rs: ­0.402; p = 0.034; 
Figure 1D). However, no statistically significant correla­
tion was observed between miR­378 levels and tumor stage 
(Supplemental Figure 2).
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Downregulation of miR-378 highlights the 
poor disease-free survival of the patients 
and improves risk stratification
The prognostic significance of miR­378 for patients’ 
outcome following radical prostatectomy was assessed by 
Kaplan­Meier survival curves (Figure 2A) and Cox regres­
sion analysis (Table 2). Although not statistically signifi­
cant, Kaplan­Meier curves (p = 0.070) and univariate Cox 
analysis (HR: 1.911; 95% CI: 0.932–3.921; p = 0.077) showed 
the unfavorable disease­free survival (DFS) and the higher 
risk for biochemical relapse of the miR­378(­) PCa patients 
compared to the miR­378(+) ones.
In order to improve patients’ risk stratification, the 
prognostic significance of miR­378 was further analyzed 
in combination with patients’ Gleason score and tumor 
stage. As indicated by Kaplan­Meier DFS curves, a more 
accurate prediction of the DFS expectancy following 
radical prostatectomy was achieved for the patients of the 
same Gleason score or tumor stage cohorts. More precisely, 
grouping patients according to Gleason score, miR­378 
loss was able to distinguish the patients with worse DFS 
outcome for both  ≤  3+4 and  ≥  4+3 groups (Figure 2B). 
Similarly, miR­378 loss was demonstrated to predict the 
poor DFS for both  ≤  pT2c and  ≥  pT3a groups compared to 
patients with miR­378 overexpression of the same cohorts 
(Figure 2C).
These findings clearly underscore the unfavorable 
outcome of the patients with reduced miR­378 levels at the 
time of treatment and the beneficial impact of miR­378 on 
the improvement of patients’ risk stratification. Addition­
ally, the ability of miR­378 loss to distinguish the patients 
with worse DFS outcome in the same Gleason score or 
tumor stage cohorts prompted us to study miR­378 prog­
nostic significance in each individual recurrence risk 
groups.
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Figure 1 miR-378 expression levels are reduced in prostate cancer patients of higher Gleason score, elevated serum PSA levels, and larger 
tumors.
Expression analysis of miR-378 levels with Gleason score (A), serum PSA concentration (B and C), and larger tumor diameter (D). p-Value 
calculated by ‘Kruskal-Wallis test’ (A and B) and ‘Spearman correlation’ (C and D). rs, Spearman correlation coefficient.
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Loss of miR-378 predicts the short-term 
relapse of the high-recurrence risk patients
NCCN guidelines for PCa were used for the classification 
of the patients according to their recurrence risk (Mohler 
et al., 2010). Kaplan­Meier analysis, as well as Cox regres­
sion analysis (Table 3), was conducted in order to study 
miR­378a prognostic value for each cohort.
Regarding ‘high’­ and ‘very high’­recurrence risk 
patients ( ≥  pT3a or Gleason score 8–10 or PSA > 20 μg/l; 
Supplemental Table 1), a significantly (p = 0.030) higher 
risk for short­term relapse was observed in the patients 
with reduced miR­378 levels (Figure 3A). In particular, a 
significantly shorter DFS expectancy was demonstrated 
for the miR­378(­) high­ and very high­risk patients 
compared to the miR­378(+) ones. For the same group 
of patients, risk­group stratification was not efficient 
enough to predict the DFS of the treated patients (p = 0.275; 
Figure  3B), strengthening, in this way, the prognostic 
potential of miR­378. Studying miR­378 levels in low­ and 
intermediate­recurrence risk patients (Supplemental 
Table 1), similar DFS intervals were demonstrated for miR­
378(­) and miR­378(+) patients.
The significance of the miR­378 expression in the prog­
nosis of ‘high’­ and ‘very high’­recurrence risk patients 
was also supported by Cox regression survival analysis. 
A significantly higher risk to relapse (HR: 2.824; 95% 
CI: 1.051–7.585; p = 0.040) was observed in the miR­378(­) 
patients compared to miR­378(+) patients by univariate 
models. For the same patients’ group, only Gleason score 
was proved to have a statistically significant prognostic 
value for the prediction of biochemical relapse. Finally, 
multivariate Cox regression models revealed prognos­
tic value of miR­378 levels for the prediction of patients’ 
DFS following treatment (HR: 4.792; 95% CI: 1.130–17.522; 
p = 0.018) independent from Gleason score, tumor stage, 
PSA, DRE, and age. Summarizing, miR­378 loss in PCa 
represents an independent prognostic marker for the pre­
diction of high­ and very high­recurrence risk patients’ 
short­term relapse.
Discussion
Since their discovery, miRNAs have emerged as pow­
erful posttranscriptional gene expression regulatory 
mediators (Bartel, 2004), and deregulated miRNA levels 
have been documented in the majority of human malig­
nancies (Calin and Croce, 2006; Bartels and Tsongalis, 
2009). Therefore, the study of miRNAs’ role in several 
100
A
B
C
p=0.070
p<0.001
p<0.001
miR-378 (+) patients
n=29; Events: 12 (41.38%)
miR-378 (-) patients
n=33; Events: 20 (60.61%)
GS≤3+4; miR-378 (+) patients
n=20; Events: 5 (20.0%)
GS≥4+3; miR-378 (+) patients
n=9; Events: 7 (77.8%)
GS≥4+3; miR-378 (-) patients
n=12; Events: 11 (91.7%)
Stage≤pT2c: miR-378 (+) patients
n=21; Events: 6 (28.6%)
Stage≤pT2c: miR-378 (-) patients
n=17; Events: 7 (41.2%)
Stage≥pT3a: miR-378 (+) patients
n=9; Events: 6 (66.7%)
Stage≥pT3a: miR-378 (-) patients
n=15; Events: 13 (86.7%)
GS≤3+4; miR-378 (-) patients
n=21; Events: 9 (42.9%)
80
60
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
40
20
0
0 12 24 36 48
Disease-free survival (months)
60 72 84
100
80
60
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
40
20
0
0 12 24 36 48
Disease-free survival (months)
60 72 84
100
80
60
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
40
20
0
0 12 24 36 48
Disease-free survival (months)
60 72 84
Figure 2 miR-378 downregulation in prostate cancer increases the 
risk for disease relapse and improves patients’ risk stratification 
according to Gleason score and tumor stage.
Kaplan-Meier curves for the disease-free survival (DFS) of the pros-
tate cancer patients according to miR-378 levels (A), Gleason score 
and miR-378 levels (B), and tumor stage and miR-378 levels (C). 
p-Value calculated by ‘Log Rank test’. GS, Gleason score.
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cancer­related molecular cascades would aid to the elu­
cidation of the clinical significance for PCa patients’ man­
agement (Schaefer et al., 2010b; Fendler et al., 2011; Larne 
et al., 2013; Lichner et al., 2013).
Using miRNA­target prediction programs, miR­378­3p 
was found to be the most frequently predicted miRNA 
candidate able to regulate both KLK2 and KLK4 expres­
sion. This is in agreement with miRNA microarray­based 
results showing downregulated miR­378 levels in PCa 
(Martens­Uzunova et al., 2012), opposite to the elevated 
expression of its KLK2 and KLK4 targets (Avgeris et  al., 
2012). Among the different variants of miR­378­3p (miR­
378a­j and miR­422a), miR­378a­3p (previously annotated 
as miR­378 or miR­422b) is the predominantly expressed 
variant of the miR­378/422a family, encoded by MIR378A, 
an intronic miRNA encoded gene embedded within the 
first intron of PPARGC1B gene in the 5q32 chromosomal 
locus.
Although MIR378A has been studied in various 
human malignancies, its function and expression profile 
has not been fully elucidated yet. MIR378A overexpres­
sion in U87 glioblastoma and MT­1 breast carcinoma cells 
was essential for cell survival, tumor growth, and angio­
genesis, through the downregulation of SuFu and Fus­1 
tumor suppressors by miR­378a­5p (Lee et al., 2007), while 
miR­378a­3p was found to be crucial for Myc­mediated cell 
transformation, following the silencing of the TOB2 anti­
proliferative factor (Feng et al., 2011). Regarding non­small 
cell lung cancer, mir­378a overexpression in NCI­H292 
cells resulted to downregulation of HMOX1 and increased 
cell proliferation and migration (Skrzypek et  al., 2013), 
while higher miR­378 levels were associated with patients’ 
brain metastasis, tumor growth, and angiogenesis of A549 
xenografts (Chen et al., 2012).
However, studies of miR­378 in the pathophysiology of 
the heart question its oncogenic properties. In particular, 
Table 2 Cox proportional regression analysis for the prediction of the PCa patients’ disease-free survival.
PCa patients
Covariant Univariate analysis 
 
Multivariate analysis 
HR  95% CIa  p-Valueb HR  95% CIa  p-Valueb
miR-378
 Positive 1.00  1.00 
 Negative 1.911  0.932–3.921  0.077  1.722  0.818–3.624  0.152
Gleason score 2.027  1.480–2.777   < 0.001  1.903  1.250–2.897  0.003
Clinical stage 1.506  1.178–1.924  0.001  1.000  0.695–1.437  0.998
PSA 1.092  1.035–1.151  0.001  1.035  0.968–1.106  0.315
Age 0.996  0.944–1.051  0.879  0.990  0.935–1.049  0.738
DRE 2.276  1.100–4.710  0.027  1.671  0.758–3.684  0.203
aConfidence interval of the estimated HR.
bTest for trend.
Table 3 Cox proportional regression analysis for the prediction of the high- and very high-recurrence risk PCa patients’ disease-free 
survival.
High- and very high-recurrence risk PCa patients
Covariant Univariate analysis Multivariate analysis
HR 95% CIa   p-Valueb HR 95% CIa   p-Valueb
miR-378
 Positive 1.00 1.00
 Negative 2.824   1.051–7.585 0.040 4.792 1.310–17.522 0.018
Gleason score 1.737   1.084–2.783 0.022 1.878 1.104–3.196 0.020
Clinical stage 1.718   0.751–3.931 0.200 0.795 0.341–1.854 0.596
PSA 1.046   0.972–1.125 0.230 0.976 0.888–1.072 0.607
Age 0.939   0.868–1.016 0.119 0.936 0.864–1.013 0.102
DRE 2.779   0.802–9.637 0.107 5.659 1.225–26.141 0.026
aConfidence interval of the estimated HR.
bTest for trend.
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reduced miR­378 levels have been found in hypertrophic 
heart growth and cardiac failure (Ganesan et  al., 2013; 
Nagalingam et al., 2013). These antihypertrophic activities 
of miR­378 are mainly exerted through the suppression of 
the MAPK/ERK and PI3K/AKT signaling pathways. More 
precisely, miR­378 overexpression blocks cardiac hyper­
trophy by preventing Ras activation and thus MAPK/ERK 
and PI3K/AKT downstream cascades, by targeting the 
GRB2 upstream mediator (Nagalingam et  al., 2013), as 
well as MAPK1 (ERK2), IGF1R, and KSR1 members of the 
MAPK pathway (Ganesan et al., 2013). The miR­378a­medi­
ated regulation of IGF1R signaling is even more critical in 
PCa pathogenesis. Overexpression of miR­378 resulted to 
the translational inhibition of IGF1R and to apoptotic cell 
death, while miR­378 knockdown launches IGF1R­related 
Akt cascade (Knezevic et al., 2012).
In order to evaluate miR­378 clinical significance for 
PCa, we measured miR­378 levels in cancerous and benign 
prostate tissues. Decreased miR­378 levels were found 
in PCa patients compared to BPH control ones. In PCa 
patients, miR­378 loss was further correlated with high 
Gleason score, tumors with larger diameter, and elevated 
serum PSA levels. Motivated by the correlation of miR­378 
loss with unfavorable prognostic markers, we analyzed 
the significance of miR­378 in the survival outcome of the 
patients. As expected, Cox regression analysis revealed a 
significantly higher risk for relapse of the patients with 
reduced miR­378 levels, and Kaplan­Meier DFS curves 
indicated the correlation of miR­378 loss with the shorter 
DFS intervals following radical prostatectomy. Interest­
ingly, miR­378 quantification was shown to be able to 
improve significantly the Gleason score­ or tumor stage­
based risk stratification of the patients.
The prognostic significance of miR­378 was further 
evaluated in ‘low’­ and ‘intermediate’­recurrence risk as 
well as in ‘high’­ and ‘very high’­recurrence risk patients. 
Interestingly, the loss of miR­378 in high­ and very high­
risk groups of patients ( ≥  pT3a or Gleason score: 8–10 or 
PSA > 20 μg/l) predicts their short­term relapse, highlight­
ing the utility of miR­378 for a more accurate prognosis 
of high­ and very high­risk group. Kaplan­Meier curves 
suggested significantly worse DFS of the patients display­
ing miR­378 loss, while univariate Cox regression analysis 
pointed out an approximately threefold higher risk for 
relapse. Multivariate models highlighted that the predic­
tion of the short­term relapse of the PCa patients with miR­
378a loss and their poor DFS is independent of Gleason 
score, tumor stage, serum PSA levels, age, and DRE. These 
results not only support a possible central role of miR­378 
in disease progression but also underscore miR­378 as a 
novel independent prognostic marker for ‘high’­ and ‘very 
high’­recurrence risk cohort.
Although prostate carcinogenesis is not the result of 
a single molecular event, ligand­independent pathways 
(outlaw pathways) of AR overactivation, especially in 
the late disease stages, are essential for disease progres­
sion and aggressiveness. Regarding ‘outlaw’ activation 
of AR, receptor­tyrosine­kinases (RTK) signaling, medi­
ated mainly by IGF1R, and IL6­ and IL8­related signaling, 
triggers AR overactivation through PI3K/AKT, MAPK, and 
JAK/STAT3 pathways, while KLK2 and KLK4 have been 
found to enhance AR activity in an androgen­independent 
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Figure 3 miR-378 loss in ‘high’- and ‘very high’-recurrence risk patients ( ≥  pT3a or Gleason score 8–10 or PSA > 20 μg/l) predicts the short-
term disease relapse following radical prostatectomy.
Kaplan-Meier curves for the disease-free survival (DFS) of the ‘high’- and ‘very high’-risk patients according to miR-378 levels (A) and to 
NCCN guidelines risk-group stratification (B). p-Value calculated by ‘Log Rank test’.
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manner (Mavridis et al., 2014). Consequently, the ability 
of miR­378 to target KLK2 and KLK4, along with IGF1R sig­
naling and key components of MAPK and AKT pathways, 
highlights a possible regulatory role of miR­378 upon AR 
signaling in prostate cells. This is in agreement with the 
observed, in our analysis, correlation of miR­378 down­
regulation with higher Gleason score and larger­diameter 
prostate tumors, as well as with the poor survival expec­
tancy of the patients.
In conclusion, in the present study, we have identified 
in silico miR­378 as a common regulator of KLK2 and KLK4 
PCa­related members of the KLK family and analyzed 
miR­378 clinical significance for the prognosis of PCa 
patients. Reduction of miR­378 levels was observed in PCa 
tissues compared to benign gland lesions. The downregu­
lation of miR­378 expression was correlated with disease 
progression, as patients with higher Gleason score tumors 
and elevated serum PSA concentrations were found to 
have significantly lower miR­378 levels. This was further 
verified by the higher risk for relapse and the worse DFS 
of the patients with lower miR­378 expression. Finally, 
in high­ and very high­recurrence risk patients, miR­378 
loss was shown to predict the short­term relapse follow­
ing treatment of PCa patients independent from Gleason 
score, tumor stage, PSA levels, and age. Overall, these 
findings highlight the reduced expression of miR­378 in 
PCa, the correlation of miR­378 downregulation with high 
Gleason score tumors and elevated serum PSA levels, 
and finally the ability of miR­378 to predict the survival 
outcome of the treated patients, supporting, in this way, 
miR­378 potential use to improve PCa prognosis.
Materials and methods
miRNA targeting prediction analysis
MiRanda, TargetScan, DIANA micro­T v3.0, miRTarget2, MicroCosm, 
PITA, RNA22, and miRWalk online available programs (see Table 1 
for links to the above­mentioned algorithms) were used for the pre­
diction of KLK2- and KLK4­targeting miRNAs via miRecords (http://
www.mirecords.umn.edu/miRecords/), miRNA body map (http://
www.mirnabodymap.org/), and miRWalk (http://www.umm.uni­
heidelberg.de/apps/zmf/mirwalk/) databases. The analyses were 
performed using the databases’ default parameters.
Study population
Prostate tissue specimens were obtained from 73 PCa patients who 
underwent radical retropubic prostatectomy (Supplemental Tables 
2 and 3) and 64 transurethral or open prostatectomy treated benign 
prostate hyperplasia (BPH) patients. Focusing on PCa patients, a tis­
sue sample of approximately 200 mg was sectioned from the periph­
eral zone of prostate gland based on the preoperative features of 
the biopsy and on macroscopic findings. The sample was thereafter 
divided into two mirror­image specimens, one of which was tested 
by a pathologist, while the other one was immediately frozen in liq­
uid nitrogen and stored at ­80°C until analysis. None of the patients 
included received hormonal therapy or radiotherapy prior to surgery. 
The last measurement of serum PSA prior to prostate biopsy and 
diagnosis, approximately 1–2 months prior to radical prostatectomy, 
was used in our analysis. Our study was approved by the ethics com­
mittee of ‘Laiko General Hospital’ and performed with respect to the 
ethical standards of the Declaration of Helsinki, as revised in 2008.
The follow­up data from 62 PCa patients were used for the 
assessment of miR­378 prognostic significance for prostate cancer, 
while 11 PCa patients were excluded from the monitoring plan due 
to either unclear follow­up data or the administration of adjuvant 
therapy before biochemical recurrence. PCa patients’ were followed­
up according to European Association of Urology (EAU) guidelines, 
and biochemical relapse was defined by two consecutive measure­
ments of serum PSA  ≥  0.2 μg/l. The National Comprehensive Cancer 
Network (NCCN) guidelines for PCa (Supplemental Table 1) were fol­
lowed for the evaluation of patients’ recurrence risk (Mohler et al., 
2010).
Extraction and polyadenylation of total RNA
Total RNA was isolated using TRI­Reagent (Molecular Research 
Center, Inc., Cincinnati, OH, USA) according to manufacturer’s 
instructions, following the pulverization of 60–120  mg of tissue 
specimen. Total RNA concentration and purity were determined 
spectrophotometrically at 260 and 280 nm, while RNA integrity was 
evaluated by agarose gel electrophoresis. Thereafter, 1 μg of total 
RNA was polyadenylated at the 3′­end in a 15­μl reaction at 37°C for 
60 min using 800 μm ATP and 1 U of Escherichia coli Poly(A) Poly­
merase (New England Biolabs Inc., Ipswich, MA, USA). Enzyme heat 
inactivation was performed at 65°C for 15 min.
First-strand cDNA synthesis
The polyadenylated total RNA was reversed transcribed in a 20­μl 
reaction containing 50 U MMLV reverse transcriptase (Invitrogen, 
Carlsbad, CA, USA), 40 U recombinant ribonuclease inhibitor (Invi­
trogen), and 0.25 μm poly(T) adapter 5′­GCGAGCACAGAATTAATAC­
GACTCACTATAGGTTTTTTTTTTTTVN­3′ (V = G, A, C and N = G, A, T, 
C) at 37°C for 60 min (Avgeris et al., 2013; Mavridis et al., 2013). The
reverse transcriptase was inactivated by heating at 70°C for 15 min.
Quantitative real-time PCR (qPCR)
Specific forward primers for the miR­378a and the small nucleolar 
RNA, C/D box 48 (SNORD48), also known as RNU48, were designed 
based on their published sequences (NCBI RefSeq accession number: 
NR_029870.1 and NR_002745.1, respectively) and in silico specificity 
evaluation. Moreover, a universal reverse primer, able to hybridize to 
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the above­mentioned poly(T) adapter, was also synthesized. The com­
bination of the 5′­GGACTGGACTTGGAGTCAGAA­3′ forward primer for 
miR­378a or the 5′­TGATGATGACCCCAGGTAACTCT­3′ forward primer 
for SNORD48 with the universal reverse primer 5′­GCGAGCACAGAAT­
TAATACGAC­3′, amplified a 67­bp miR­378­ and a 105­bp SNORD48­
specific amplicon, respectively (Avgeris et al., 2013; Mavridis et al., 
2013).
The qPCR assay was performed in the 7500 Real­Time PCR Sys­
tem (Applied Biosystems, Carlsbad, CA, USA), and the 10­μl reaction 
consists of Kapa SYBR® Fast Universal 2x qPCR Master Mix (Kapa Bio­
systems, Inc., Woburn, MA, USA), 200 nm of each PCR primer, and 0.2 
ng of cDNA. The thermal protocol comprised of a 3­min polymerase 
activation step at 95°C, 40 cycles of denaturation at 95°C for 15 s, and 
a primer annealing and extension step at 60°C for 1 min. Following 
the amplification, melting curve analysis and agarose gel electropho­
resis were used for the determination of specific reaction products 
compared to nonspecific ones or primer dimmers. Using serial dilu­
tions of a control cDNA as template, calibration curves for miR­378 
and SNORD48 amplification were generated covering six orders of 
magnitude (Supplemental Figure 3). The linear increases of miR­378 
(y = ­3.47x+43.49; r2 = 0.991) and SNORD48 (y = ­3.32x+38.02; r2 = 0.999) 
amplification highlighted the 94.3% and 99.9% reaction efficiencies, 
respectively, as well as the absence of PCR inhibition by the template.
Relative quantification (RQ) of miR­378 was performed using the 
2­ΔΔCT method, where the LNCaP prostate cancer cell line was used as 
our assay calibrator and SNORD48 as an endogenous reference con­
trol (Larne et al., 2009). Duplicate reactions were performed for each 
tested sample, and the average Ct was calculated for the quantifica­
tion analysis. No template controls, reverse transcriptase­negative 
controls, Poly(A) polymerase­negative controls, and DNA template 
controls generated undetectable Ct or  > 36.
Statistical analysis
The analysis of miR­378 levels between PCa and BPH patients was 
performed using the Mann­Whitney U­test. Univariate logistic regres­
sion analysis, calculating log10miR­378 odds ratio (OR) and ROC curve 
analysis were used for the evaluation of miR­378 ability to discrimi­
nate PCa from BPH patients.
Differences in miR­378 expression levels among patients of 
different Gleason score, tumor stages, PSA group, or digital rec­
tal examination (DRE) were analyzed using Mann­Whitney U and 
Kruskal­Wallis tests. The correlation of miR­378 expression with PCa 
patients’ PSA levels and tumor diameter was assessed by Spear­
man’s correlation coefficient (rs). Using the X­tile algorithm, the 3.12 
RQ units of miR­378 (equal to the 52nd percentile of the PCa patients’ 
cohort) were adopted as an optimal cutoff to classify PCa patients 
into miR­378(+) and miR­378(­) cohorts, expressing higher and lower 
miR­378 levels, respectively.
The prognostic significance of miR­378 was evaluated by Kaplan­
Meier survival analysis, using log rank test, and Cox proportional 
hazards regression models. Univariate and multivariate Cox regres­
sion models were employed for the calculation of the hazard ratio 
(HR) of miR­378, Gleason score, tumor stage, serum PSA, patient’s 
age, and DRE.
Acknowledgments: This research has been co­financed 
by the European Union (European Social Fund­ESF) 
and Greek national funds through the Operational Pro­
gram ‘Education and Lifelong Learning’ of the National 
Strategic Reference Framework (NSRF)­Research Fund­
ing Program: THALES, Investing in knowledge society 
through the European Social Fund (UoA – BIOPROMO, 
MIS 377046).
References
Andriole, G.L., Crawford, E.D., Grubb, R.L., 3rd, Buys, S.S., 
Chia, D., Church, T.R., Fouad, M.N., Gelmann, E.P., Kvale, P.A., 
Reding, D.J., et al. (2009). Mortality results from a rand-
omized prostate-cancer screening trial. N. Engl. J. Med. 360, 
1310–1319.
Avgeris, M., Mavridis, K., and Scorilas, A. (2010). Kallikrein-related 
peptidase genes as promising biomarkers for prognosis and 
monitoring of human malignancies. Biol. Chem. 391, 505–511.
Avgeris, M., Stravodimos, K., and Scorilas, A. (2011). Kallikrein-
related peptidase 4 gene (KLK4) in prostate tumors: quan-
titative expression analysis and evaluation of its clinical 
significance. Prostate 71, 1780–1789.
Avgeris, M., Mavridis, K., and Scorilas, A. (2012). Kallikrein-
related peptidases in prostate, breast, and ovarian cancers: 
from pathobiology to clinical relevance. Biol. Chem. 393, 
301–317.
Avgeris, M., Stravodimos, K., Fragoulis, E.G., and Scorilas, A. (2013). 
The loss of the tumour-suppressor miR-145 results in the 
shorter disease-free survival of prostate cancer patients. Br. J. 
Cancer 108, 2573–2581.
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell 116, 281–297.
Bartels, C.L. and Tsongalis, G.J. (2009). MicroRNAs: novel biomark-
ers for human cancer. Clin. Chem. 55, 623–631.
Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human 
tissue kallikreins: physiologic roles and applications in cancer. 
Mol. Cancer Res. 2, 257–280.
Calin, G.A. and Croce, C.M. (2006). MicroRNA signatures in human 
cancers. Nat. Rev. Cancer 6, 857–866.
Chen, L.T., Xu, S.D., Xu, H., Zhang, J.F., Ning, J.F., and Wang, S.F. 
(2012). MicroRNA-378 is associated with non-small cell lung 
cancer brain metastasis by promoting cell migration, invasion 
and tumor angiogenesis. Med. Oncol. 29, 1673–1680.
Chow, T.F., Crow, M., Earle, T., El-Said, H., Diamandis, E.P., and 
Yousef, G.M. (2008). Kallikreins as microRNA targets: an in 
silico and experimental-based analysis. Biol. Chem. 389, 
731–738.
Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., 
Young, C.Y., Klee, G.G., Tindall, D.J., and Bostwick, D.G. (1997). 
Human glandular kallikrein 2 (hK2) expression in prostatic 
intraepithelial neoplasia and adenocarcinoma: a novel pros-
tate cancer marker. Urology 49, 857–862.
Fendler, A., Stephan, C., Yousef, G.M., and Jung, K. (2011). 
 MicroRNAs as regulators of signal transduction in urological 
tumors. Clin. Chem. 57, 954–968.
Feng, M., Li, Z., Aau, M., Wong, C.H., Yang, X., and Yu, Q. (2011). 
Myc/miR-378/TOB2/cyclin D1 functional module regulates 
oncogenic transformation. Oncogene 30, 2242–2251.
1104   M. Avgeris et al.: miR-378 loss predicts PCa short-term relapse
Freedland, S.J. (2011). Screening, risk assessment, and the 
approach to therapy in patients with prostate cancer. Cancer 
117, 1123–1135.
Ganesan, J., Ramanujam, D., Sassi, Y., Ahles, A., Jentzsch, C., 
 Werfel, S., Leierseder, S., Loyer, X., Giacca, M., Zentilin, L., 
et al. (2013). MiR-378 controls cardiac hypertrophy by com-
bined repression of mitogen-activated protein kinase pathway 
factors. Circulation 127, 2097–2106.
Herrala, A.M., Porvari, K.S., Kyllonen, A.P., and Vihko, P.T. (2001). 
Comparison of human prostate specific glandular kallikrein 
2 and prostate specific antigen gene expression in prostate 
with gene amplification and overexpression of prostate 
specific glandular kallikrein 2 in tumor tissue. Cancer 92, 
2975–2984.
Klokk, T.I., Kilander, A., Xi, Z., Waehre, H., Risberg, B., 
 Danielsen, H.E., and Saatcioglu, F. (2007). Kallikrein 4 is a 
proliferative factor that is overexpressed in prostate cancer. 
Cancer Res. 67, 5221–5230.
Knezevic, I., Patel, A., Sundaresan, N.R., Gupta, M.P., Solaro, R.J., 
Nagalingam, R.S., and Gupta, M. (2012). A novel cardiomyo-
cyte-enriched microRNA, miR-378, targets insulin-like growth 
factor 1 receptor: implications in postnatal cardiac remodeling 
and cell survival. J. Biol. Chem. 287, 12913–12926.
Larne, O., Edsjo, A., Bjartell, A., and Ceder, Y. (2009). Development 
of a miRNA assay for prostate cancer detection. Eur. Urol. 
Suppl. 8, S316.
Larne, O., Martens-Uzunova, E., Hagman, Z., Edsjo, A., Lippolis, G., 
den Berg, M.S., Bjartell, A., Jenster, G., and Ceder, Y. (2013). 
miQ–a novel microRNA based diagnostic and prognostic tool 
for prostate cancer. Int. J. Cancer 132, 2867–2875.
Lawrence, M.G., Lai, J., and Clements, J.A. (2010). Kallikreins on 
steroids: structure, function, and hormonal regulation of 
prostate-specific antigen and the extended kallikrein locus. 
Endocr. Rev. 31, 407–446.
Lee, D.Y., Deng, Z., Wang, C.H., and Yang, B.B. (2007). 
 MicroRNA-378 promotes cell survival, tumor growth, and 
angiogenesis by targeting SuFu and Fus-1 expression. Proc. 
Natl. Acad. Sci. USA 104, 20350–20355.
Lichner, Z., Fendler, A., Saleh, C., Nasser, A.N., Boles, D., 
 Al-Haddad, S., Kupchak, P., Dharsee, M., Nuin, P.S., 
Evans, K.R., et al. (2013). MicroRNA signature helps distinguish 
early from late biochemical failure in prostate cancer. Clin. 
Chem. 59, 1595–1603.
Martens-Uzunova, E.S., Jalava, S.E., Dits, N.F., van Leenders, G.J., 
Moller, S., Trapman, J., Bangma, C.H., Litman, T., Visakorpi, T., 
and Jenster, G. (2012). Diagnostic and prognostic signatures 
from the small non-coding RNA transcriptome in prostate can-
cer. Oncogene 31, 978–991.
Mavridis, K. and Scorilas, A. (2010). Prognostic value and biological 
role of the kallikrein-related peptidases in human malignan-
cies. Future Oncol. 6, 269–285.
Mavridis, K., Stravodimos, K., and Scorilas, A. (2013). Downregula-
tion and prognostic performance of microRNA 224 expression 
in prostate cancer. Clin. Chem. 59, 261–269.
Mavridis, K., Avgeris, M., and Scorilas, A. (2014). Targeting 
kallikrein-related peptidases in prostate cancer. Exp. Opin. 
Ther. Targets 18, 365–383.
Mohler, J., Bahnson, R.R., Boston, B., Busby, J.E., D’Amico, A., 
 Eastham, J.A., Enke, C.A., George, D., Horwitz, E.M., Huben, R.P., 
et al. (2010). NCCN clinical practice guidelines in oncology: pros-
tate cancer. J. Natl. Compr. Canc. Netw. 8, 162–200.
Nagalingam, R.S., Sundaresan, N.R., Gupta, M.P., Geenen, D.L., 
Solaro, R.J., and Gupta, M. (2013). A cardiac-enriched micro-
RNA, miR-378, blocks cardiac hypertrophy by targeting Ras 
signaling. J. Biol. Chem. 288, 11216–11232.
Pasic, M.D., Olkhov, E., Bapat, B., and Yousef, G.M. (2012). Epige-
netic regulation of kallikrein-related peptidases: there is a 
whole new world out there. Biol. Chem. 393, 319–330.
Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., 
 Tammela, T.L., and Visakorpi, T. (2007). MicroRNA expression 
profiling in prostate cancer. Cancer Res. 67, 6130–6135.
Schaefer, A., Jung, M., Mollenkopf, H.J., Wagner, I., Stephan, C., 
Jentzmik, F., Miller, K., Lein, M., Kristiansen, G., and Jung, K. 
(2010a). Diagnostic and prognostic implications of microRNA 
profiling in prostate carcinoma. Int. J. Cancer 126, 1166–1176.
Schaefer, A., Stephan, C., Busch, J., Yousef, G.M., and Jung, K. 
(2010b). Diagnostic, prognostic and therapeutic implications of 
microRNAs in urologic tumors. Nat. Rev. Urol. 7, 286–297.
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., 
Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. 
(2009). Screening and prostate-cancer mortality in a rand-
omized European study. N. Engl. J. Med. 360, 1320–1328.
Skrzypek, K., Tertil, M., Golda, S., Ciesla, M., Weglarczyk, K., 
 Collet, G., Guichard, A., Kozakowska, M., Boczkowski, J., 
Was, H., et al. (2013). Interplay between heme oxygenase-1 and 
miR-378 affects non-small cell lung carcinoma growth, vasculari-
zation, and metastasis. Antioxid. Redox Signal. 19, 644–660.
Wach, S., Nolte, E., Szczyrba, J., Stohr, R., Hartmann, A., Orntoft, T., 
Dyrskjot, L., Eltze, E., Wieland, W., Keck, B., et al. (2012). Micro-
RNA profiles of prostate carcinoma detected by multiplatform 
microRNA screening. Int. J. Cancer 130, 611–621.
Supplemental Material: The online version of this article (DOI: 
10.1515/hsz-2014-0150) offers supplementary material, available to 
authorized users.
